CoMind: 10 Key Things You Must Know

Overview

CoMind is a pioneering neurotechnology company based in London that is revolutionizing brain healthcare through non-invasive monitoring technology. Founded in 2018, CoMind has developed an innovative neurosensing platform that provides clinicians with unprecedented access to critical brain physiological signals without the need for risky invasive procedures. This technology marks a transformative leap in brain health monitoring, enabling better patient safety, enhanced clinical outcomes, and new opportunities in precision medicine. From intensive care units to surgical and emergency settings, CoMind’s work is reshaping how brain function is measured and treated. As you explore this article, discover how CoMind’s breakthrough innovations, business growth, and clinical impact are poised to change the future of neurological care.

1. Founded with a Vision to Transform Brain Monitoring

CoMind was founded in 2018 by James Dacombe and Christina Franzeskides with a mission to redefine brain monitoring and treatment. The company emerged from a vision to develop a device that avoids the dangerous invasiveness of traditional brain monitoring, such as drilling into the skull, while delivering precise, multi-parameter brain health data. Headquartered in London, CoMind has grown into a vibrant team of approximately 60-70 employees specializing in neuroscience, neuroimaging, photonics, and AI-powered medical device development. The company’s founding purpose is deeply rooted in improving patient outcomes through accessible, safe, and continuous brain monitoring technology.

2. Breakthrough Technology: Non-Invasive, Multi-Parameter Measurement

At the heart of CoMind’s innovation is their flagship device, CoMind One. This technology uses low-power laser light combined with advanced photonics techniques to non-invasively measure multiple crucial brain parameters simultaneously. Unlike existing invasive monitors that require drilling, CoMind One measures cerebral blood flow, cerebral autoregulation, and intracranial pressure through the scalp at the patient’s bedside. This unique combination was never before possible with a single non-invasive device, positioning CoMind as a pioneer in the medical device market for neurocritical care.

3. Clinical Impact: Enhancing Patient Safety and Outcomes

Continuous and accurate brain monitoring is critical for treating patients with traumatic brain injury, stroke, or during surgery and intensive care. CoMind’s technology provides clinicians with real-time, multi-dimensional data, allowing for earlier intervention and personalized treatment plans. This promise of improved neurological care is significant because current invasive methods are risky and not suitable for many patients, while alternative non-invasive techniques are often imprecise. By reducing risk and increasing diagnostic information quality, CoMind is helping redefine standards of care in brain health.

4. AI-Powered Platform – CoVision

Complementing its hardware, CoMind has developed an AI-based analytics platform called CoVision. CoVision harnesses machine learning to analyze complex neuromonitoring data, delivering predictive insights to healthcare professionals. This capability enables clinicians to anticipate potential complications and optimize treatment strategies proactively. The integration of AI with the neuromonitoring device underscores CoMind’s commitment to precision medicine and represents a leap toward smarter, data-driven neurological care that could significantly improve patient outcomes in hospital settings.

5. Substantial Funding and Investor Confidence

CoMind has successfully raised over $100 million in funding to accelerate product development, clinical trials, and global market expansion. The latest round, led by Plural, included participation from prominent investors such as Octopus Ventures, LocalGlobe, Angelini Ventures, Crane Venture Partners, and several respected angel investors. This strong financial backing reflects broad confidence in CoMind’s disruptive potential within the medical device and neurotechnology sectors. It has positioned the company well for upcoming regulatory approvals, including in the United States.

6. Regulatory and Clinical Trials Progress

As of 2025, CoMind is actively enrolling patients in early feasibility clinical trials to validate and demonstrate the safety and efficacy of CoMind One. These efforts are crucial for meeting regulatory requirements which will enable the company to bring its device to market internationally. Targeted for launch in 2027, CoMind aims to make bedside brain monitoring accessible in a wide range of clinical environments, from operating rooms to neurocritical care units. Their approach promises to expedite accurate brain health assessment without the downtime and risk associated with current invasive techniques.

7. Leadership and Expertise Driving Innovation

CoMind benefits from a leadership team with a deep blend of medical technology expertise, clinical experience, and entrepreneurial spirit. CEO James Dacombe, a generational founder who started the company at a young age, brings vision and determination. The board includes renowned figures such as Frank Fischer, an experienced MedTech founder and chairman, and Dr. Michael Tarnoff, MD, with significant healthcare executive leadership experience. This high-caliber team ensures that CoMind’s innovations align well with clinical realities and healthcare market needs.

8. Disease Applications and Market Potential

CoMind’s technology has broad applications in neurological conditions requiring precise brain monitoring, including head trauma, stroke, neurosurgery, and intensive care management. The global market for brain monitoring devices is sizable and growing due to increasing awareness of neurological health and the need for safer, more accurate diagnostics. By offering a non-invasive, affordable, and portable system, CoMind is uniquely positioned to capture a significant share of this market and potentially drive new standards of care worldwide.

9. Collaborative Research and Industry Recognition

The company actively collaborates with leading biomedical optics and neuroscience communities, participating in conferences such as the European Conference on Biomedical Optics (ECBO). These engagements help CoMind stay at the forefront of scientific innovation while validating its technology within expert circles. Industry recognition also comes from multiple patent filings and endorsements by key venture capitalists who regard CoMind’s approach as groundbreaking, with potential to dramatically improve neurological diagnostics and treatment.

10. The Future of Brain Computing Interfaces

Beyond immediate clinical uses, CoMind is laying the foundation for next-generation brain-computer interface technologies. Their vision includes evolving from diagnostic neuromonitoring to seamless neural interfaces that link directly to artificial intelligence systems. This future focus could enable new applications in cognitive enhancement, neurological disorder management, and even human-machine interaction. CoMind’s work today is therefore not only advancing medical care but also contributing to the frontier of neurotechnology innovation globally.

Conclusion

CoMind stands out as a trailblazer in neurotechnology, dedicated to transforming brain health monitoring through non-invasive, multi-parameter sensing and AI-driven insights. Its innovative CoMind One device tackles long-standing clinical challenges by replacing invasive brain monitoring with a safer, more accessible alternative. Supported by strong leadership, collaborative research efforts, and substantial investment, CoMind is well poised to redefine neurological care and expand the capabilities of brain-computer interfaces. As healthcare embraces precision medicine, CoMind’s advances prompt us to consider: How will improved brain monitoring reshape treatment outcomes and the future of brain-machine synergy?